69 results about "Viral isolate" patented technology

A method of predicting the virulence of a new or uncharacterized PRRS virus isolate is provided wherein the isolate is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and / or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and / or viremia magnitude of a PRRS virus isolate of known virulence, as a measure of the virulence of the new or uncharacterized isolate. Additionally, a method of selecting an isolate for inclusion in an immunogenic composition based on the predicted virulence is also provided, together with compositions incorporating attenuated forms of viruses predicted to be virulent.

Disclosed are oligonucleotide amplification primers and detection probes specific for the amplification and detection of pathogenic organisms, including for example, specific Influenza A H1N1 viral isolates. Also disclosed is a biological organism identification kit including the disclosed nucleic acid probes and primers, as well as thermal cycling reagents that is both portable and durable, and may also be self-contained for remote, or in-field analysis and identification of particular influenza isolates from a variety of biological specimen types.

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and / or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and / or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

Disclosed are oligonucleotide amplification primers and detection probes specific for the amplification and detection of pathogenic organisms, including for example, specific Influenza A H1N1 viral isolates. Also disclosed is a biological organism identification kit including the disclosed nucleic acid probes and primers, as well as thermal cycling reagents that is both portable and durable, and may also be self-contained for remote, or in-field analysis and identification of particular influenza isolates from a variety of biological specimen types.

This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+ cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies. This invention further provides: methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1 which comprises contacting the CD4+ cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion; and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1 which comprises contacting the CD4+ cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion.

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and / or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and / or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

The invention discloses a primary isolated culture method for dairy cow mammary epithelial cells. The primary isolated culture method comprises steps as follows: mammary tissue of a dairy cow in the lactation period is shorn into tissue blocks, the tissue blocks are digested with collagenase / hyaluronidase digestive juice, a culture dish is inoculated with the digested chylous tissue blocks for culture, cells get free from tissue on peripheries of the tissue blocks after 1-2 days and grow along the wall of the culture dish, fusiform fibroblast is removed with a mechanical scraping method every day during culture, and initial passage is performed when a large quantity of cobblestone-like mammary epithelial cells grow in clusters and in patches and are mutually fused after about 4-5 days. During initial passage, a little fibroblast which is probably mixed is eliminated with trysin with a differential digestive method, and the dairy cow mammary epithelial cells with high purity are obtained. The mammary epithelial cells can emigrate from chylous tissue in a short time; a little mixed fibroblast is removed mainly with a mechanical scraping method, and accordingly, the obtained mammary epithelial cells are seldom damaged and are high in purity.

The present invention discloses methods for producing and / or propagating virus particles, such as influenza virus particles, that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle. The invention also provides a method for selective propagation of a set of virus particles, such as influenza virus particles present in an influenza isolate, which have an affinity for receptors comprising a specific glycosylation residue.

A novel immunogenic HIV-1 Env, particularly gp120, DNA construct is disclosed in which either the V1 / V2 loop and the V4 loop, or all three variable loops, including V3, are replaced with a V3 sequence each of which is from a different viral isolate. Preferably, each replacement V3 loop is a consensus sequence of V3 of a different clade. Such constructs are useful as immunogens as each presents three independent V3 epitopes, so that the immunized subject generates a more broadly reactive neutralizing antibody response than with conventional gp120 or V3 DNA or polypeptide immunogens. Also disclosed are methods of using the DNA construct to immunize a mammal, preferably a human, particularly in a priming regiment in which the DNA immunogen is followed by administration of a V3 fusion protein boosting immunogen.

The invention provides a Seneca valley virus SVV-ZM-201801 and an application thereof. Separation is performed from pig tissues, and sub-culture and plaque purification are performed, so that the Seneca valley virus is obtained. The separated strain can be stably proliferated on sub-culture cells, typical cytopathic effects are formed, and the virus titer is as high as 108.5-1010.5TCID50 / mL. The separated strain does not have obvious pathogenicity on piggies. The Seneca valley virus separated strain has good proliferating properties, and is good in immunogenicity. Vaccines prepared from the separated strain can induce the piggies to generate high-level neutralizing antibodies, and powerful technical support is provided for effective prevention and control of the Seneca valley virus.

This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1 / VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1 / VK1#16, and clone 21 containing the recombinant genes B4DIVHv1 / VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.

The invention relates to the technical field of cells, in particular to a freezing medium, application thereof and an adipose tissue freezing method. The freezing medium comprises a basic culture solution, an NEAA (non-essential amino acid), DMSO, glycerol and 1,2-propanediol, and has a good protection effect on adipose tissue. Cells in adipose tissue which is thawed after being frozen by the freezing medium keep good activity. The success rate of obtaining adipose-derived stem cells by primary isolated culture is 100 percent.

The invention is related to a method for selecting an influenza virus for growth on tissue culture cells to produce a tissue-culture adapted viral isolate. The invention also includes vaccines produced from the isolate.